Cellebrite DI (NASDAQ:CLBT) Hits New 12-Month High – Here’s What Happened

Cellebrite DI Ltd. (NASDAQ:CLBT) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $24.85 and last traded at $24.88, with a volume of 1113286 shares changing hands. The stock had previously closed at $24.04.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Needham & Company LLC raised their price target on Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Craig Hallum lifted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $21.57.

Cellebrite DI Trading Up 2.1 %

The company has a market cap of $5.35 billion, a PE ratio of -16.77, a P/E/G ratio of 3.55 and a beta of 1.47. The business’s 50-day simple moving average is $21.98 and its 200-day simple moving average is $18.63.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. During the same quarter in the previous year, the firm posted $0.09 EPS. The business’s revenue was up 27.0% compared to the same quarter last year. On average, research analysts predict that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Several institutional investors and hedge funds have recently made changes to their positions in CLBT. Juncture Wealth Strategies LLC raised its stake in shares of Cellebrite DI by 0.8% in the 4th quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company’s stock valued at $1,322,000 after purchasing an additional 505 shares during the period. Strategic Advisors LLC raised its position in Cellebrite DI by 3.4% in the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock valued at $641,000 after buying an additional 950 shares during the last quarter. Tower View Wealth Management LLC lifted its stake in Cellebrite DI by 1.2% in the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock valued at $2,200,000 after acquiring an additional 1,500 shares in the last quarter. Quarry LP acquired a new position in Cellebrite DI during the 3rd quarter worth approximately $27,000. Finally, Advisors Asset Management Inc. grew its stake in shares of Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after acquiring an additional 1,742 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.